

1                                   **Performance of different nebulizers in clinical use for**  
2                                   **Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)**

3  
4                                   Short title: Technical characterisation of PIPAC nebulizers

5  
6                                   Daniel Göhler, Dipl.-Ing.<sup>1,2</sup>, Kathrin Oelschlägel, Dipl.-Ing<sup>1</sup>, Mehdi Ouaiassi, Prof, MD,  
7                                   PhD<sup>3,4</sup>, Urs Giger-Pabst, Prof, MD<sup>3,5</sup>

8  
9                                   <sup>1</sup> Topas GmbH, Dresden, Germany

10                                  <sup>2</sup> Research Group Mechanical Process Engineering, Institute of Process Engineering and  
11                                  Environmental Technology, Technische Universität Dresden, Dresden, Germany

12                                  <sup>3</sup> EA4245 Transplantation, Immunology, Inflammation, Université de Tours, France

13                                  <sup>4</sup> Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver  
14                                  Transplant Surgery, University Hospital of Tours, France

15                                  <sup>5</sup> Fliedner Fachhochschule, University of Applied Science Düsseldorf, Düsseldorf, Germany

16  
17  
18                                  **Corresponding author:**

19                                  Urs Giger-Pabst, MD

20                                  University of Applied Science

21                                  Fliedner Fachhochschule

22                                  Geschwister-Aufricht-Straße 9

23                                  40489 Düsseldorf, Germany

24                                  E-Mail: [ursgiger@gmx.net](mailto:ursgiger@gmx.net)

25                                  Phone: +49 163 729 44 07

26  
27                                  **Key words**

28                                  Pressurized Intraperitoneal Aerosol Chemotherapy, PIPAC, aerosol droplet size, gravimetry,  
29                                  Nebulizer, MCR-4 Topol<sup>®</sup>, HurriChem<sup>™</sup>, QuattroJet

30                                  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 31 **Author Contributions**

32 Daniel Göhler and Urs Giger-Pabst: study design, experiments, data acquisition, data  
33 interpretation and drafting of manuscript.

34 Kathrin Oelschlägel and Mehdi Ouaiissi: critical revision for important intellectual content of  
35 the manuscript according to their field of research.

## 36 **Disclosure**

37 Strictly academic study supported by institutional funds. All authors have no conflicts of  
38 interest or financial ties to declare.

## 39 **Data Availability Statement**

40 All relevant data are within the manuscript. Raw data will be provided by the corresponding  
41 author upon request.

## 42 **Legal background**

43 Purely technical analyses without the use of biological material or patients requiring no specific  
44 legal authorization or ethics vote.

## 45 **Acknowledgments**

46 The authors thank Professor Marc Pocard, Hepato-Biliary-Pancreatic Gastrointestinal Surgery  
47 and Liver Transplantation, Pitié Salpêtrière Hospital, AP-HP, F-75013 Paris, France, for  
48 providing a HurriChem™ (ThermaSolutions, White Bear Lake, MN, USA) nozzle.

49

50 **Abstract**

51 *Objective:* Technical ex-vivo comparison of commercial nebulizer nozzles used for Pressurized  
52 Intraperitoneal Aerosol Chemotherapy (PIPAC).

53 *Methods:* The performance of four different commercial nebulizer nozzles (Nebulizer;  
54 HurriChem™; MCR-4 TOPOL®; QuattroJet) was analysed concerning: i) technical design and  
55 principle of operation, ii) operational pressure as function of the liquid flow rate, iii) droplet  
56 size distribution via laser diffraction spectrometry, iv) spray cone angle, spray cone form as  
57 well as horizontal drug deposition by image-metric analyses and v) chemical resistance via  
58 exposing to a cytostatic solution and chemical composition by means of spark optical emission  
59 spectral analysis.

60 *Results:* The Nebulizer shows quasi an identical technical design and thus also a similar  
61 performance (e.g., mass median droplet size of 29 µm) as the original PIPAC nozzles (MIP/  
62 CapnoPen). All other nozzles show more or less a performance deviation to the original PIPAC  
63 nozzles. The HurriChem™ has a similar design and principle of operation as the Nebulizer, but  
64 provides a finer aerosol (22 µm). The principle of operation of MCR-4 TOPOL® and QuattroJet  
65 differ significantly from that of the original PIPAC nozzle technology. The MCR-4 TOPOL®  
66 offers a hollow spray cone with significantly larger droplets (50 µm) than the original PIPAC  
67 nozzles. The QuattroJet generates an aerosol (22 µm) similar to that of the HurriChem™ but  
68 with improved spatial drug distribution.

69 *Conclusion:* The availability of new PIPAC nozzles is encouraging but can also have a negative  
70 impact if their performance and efficacy is unknown. It is recommended that PIPAC nozzles  
71 that deviate from the current standard should be subject to bioequivalence testing and  
72 implementation in accordance with the IDEAL-D framework prior to routine clinical use.

73

## 74 **1 Introduction**

75 More than a decade ago, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) was  
76 introduced clinically as a new approach to deliver intraperitoneal chemotherapy to patients  
77 suffering from end-stage peritoneal surface malignancies. Using a high-pressure injector  
78 connected to a specially designed PIPAC nozzle, liquid chemotherapeutic drugs are aerosolised  
79 during laparoscopic surgery within the capnoperitoneum. This approach is expected to have a  
80 better spatial distribution pattern, greater depth of penetration, and higher drug concentration in  
81 the tissue than conventional liquid intraperitoneal chemotherapy [1, 2]. Clinical data from phase  
82 I/II and larger mono- and multicentre case series regarding safety, feasibility, and oncologic  
83 efficacy are encouraging. While the therapeutic role of PIPAC is still unclear [3], prospective  
84 randomized PIPAC trials are underway and their results are eagerly awaited [4, 5].

85 For over a decade, only the original PIPAC nozzle was available for clinical use, with more  
86 than 18`000 documented clinical applications worldwide were projected by the end of 2022 [3].  
87 To ensure comparability of the outcome data, much efforts was spent to standardize PIPAC  
88 therapy worldwide [6, 7]. But more recently, new nebulizer devices are also in clinical use.  
89 While the technical and clinical performance data of the original PIPAC nozzle has been  
90 extensively studied in pre- and clinical settings [3, 8, 9], no or only very limited comparative  
91 data are available for the new PIPAC nozzles. Oncological surgeons around the world are now  
92 faced with the question of whether these newer nozzles are equivalent to the original nozzle  
93 technology or perhaps even have technical/functional advantages with a potentially better  
94 oncological outcome?

95 On the basis of the methodological findings regarding the technical characterisation of the  
96 original PIPAC nozzle [8], the current study deals with the comparative performance  
97 characterisation of four commercial nebulizers as nowadays used for PIPAC.

98

## 99 **2 Materials and Methods**

### 100 **2.1 Examined PIPAC nozzles**

101 Four commercial single-substance PIPAC nozzles for intraperitoneal drug aerosolization were  
102 examined, i.e.,

- 103 • Nebulizer, Model 770-12, REGER Medizintechnik, Villingendorf, Germany (A),

- 104 • HurriChem™, ThermaSolutions, White Bear Lake, MN, United States of America (B),  
105 • MCR-4 TOPOL®, SKALA-Medica, Soběslav, Czech Republic (C),  
106 • QuattroJet, Model 770-14, REGER Medizintechnik, Villingendorf, Germany (D).

107 After the experiments, all nozzles were cut-open longitudinally in the middle in a 180° angle  
108 by means of a computerized numerical control milling machine to study their principles of  
109 operation. In addition, also the dimensions of the nozzle outlet orifices were examined by light  
110 microscopy (SMZ1500, Nikon, Tokyo, Japan).

## 111 2.2 *Barometric characterisation of operational pressure as function of liquid flow rate*

112 To characterise the operational pressure over the volumetric liquid flow rate, the nozzles were  
113 connected via high-pressure hose lines with a high-pressure injector (ACCUTRON® HP-D,  
114 MEDTRON AG, Saarbrücken, Germany) to push the test liquid (Glucosterile 5%, Fresenius  
115 Kabi GmbH, Germany) through the nozzles. The operational pressure induced by the liquid  
116 flow rate was determined by means of a glycerine-filled bourdon gauge (MA7U-25, JRA  
117 Maschinenteile und Geräte GmbH, Reichenbach, Germany), which was implemented in the  
118 high-pressure line. For the analyses, the volumetric liquid flow rate was increased stepwise  
119 either by 0.1 ml/s (for nozzles A, B and D) or by 0.2 ml/s (for nozzle C) until the maximum  
120 permitted pressure of 21 bar of the high-pressure injector was reached. For nozzle D, only the  
121 axial nozzle was tested - the horizontal nozzles were sealed watertight. Analogous to [8],  
122 measurement values were taken at steady state conditions of the aerosolization process and all  
123 analyses were repeated three times.

## 124 2.3 *Granulometric characterisation of droplet size distributions*

125 The droplet size distributions of the aerosols generated from the test liquid (Glucosterile 5%,  
126 Fresenius Kabi GmbH, Germany) were characterised by laser diffraction spectrometry  
127 (PW180-C spray particle size analyser, Jinan K-Ring Technology Co., Ltd, Shandong, China)  
128 over a size range of (0.57 - 780) µm. The outlets of the PIPAC nozzles were arranged via a  
129 tripod in a distance of 5 mm perpendicular to the centre of the free-accessible red laser beam.  
130 To characterise the aerosolization performance, all analyses were performed contemporaneous  
131 with the barometric characterisation of the operational pressure for various liquid flow rates.  
132 Analogous to [8], measurement values were taken at steady state conditions of the  
133 aerosolization process and all analyses were repeated three times.

134 **2.4 Image-metric characterisation of spray cone angles, form and horizontal drug**  
135 **deposition areas**

136 The spray cone angles, the form of the spray cones and the horizontal drug deposition area were  
137 characterised with different test liquids at nozzle-specific operation conditions as recommended  
138 by the manufacturers, i.e., at a volumetric liquid flow rate of 0.5 ml/s for the nozzles A, B, at  
139 2.0 ml/s for nozzle C and 1.5 ml/s for nozzle D. The former two characteristics were evaluated  
140 on the base of a 5 wt.-% aqueous glucose solution (Glucosterile 5%, Fresenius Kabi GmbH,  
141 Germany), while the latter characteristic was assessed by operating the nozzles with undiluted  
142 royal blue ink (Pelikan Tinte 4001<sup>®</sup>, Hannover, Germany).

143 For the spray cone angle analyses, the nozzles were fixed on a tripod and vertically aligned.  
144 Photographic images were taken with a camera that was perpendicular positioned to the nozzle  
145 direction. The images were in-silico processed by overlaying with a digital 360° full-circle  
146 protractor for determining the spray cone angles.

147 The form of the spray cones was visualized by means of a line laser (GCL 2-15, Robert Bosch  
148 Power Tools GmbH, Leinfelden-Echterdingen, Germany) positioned in distance of 60 mm from  
149 the nozzle orifice at right angle into the spray cone. Fully evaluated spray cone forms were  
150 finally documented photographically.

151 The horizontal drug deposition on a level-aligned blotting paper was examined by operating the  
152 vertically aligned nozzles with a distance of 60 mm between the blotting paper and the nozzle  
153 orifice. The blotting paper was exposed for 3 s to the fully-developed spray jet. To achieve this,  
154 a mechanical diaphragm was placed in front of the spray jet. The diaphragm was opened  
155 automatically within 0.1 s, when the aerosol jet showed steady state nebulisation condition.

156 **2.5 Assessing of chemical resistance and chemical composition**

157 To assess the chemical resistance of the nozzle material against chemotherapeutic drugs, the  
158 nozzles were at first exposed to a cytostatic solution for 12 hours and afterwards stored in the  
159 dark at room temperature for 12 days within petri dishes. The chosen cytostatic solution was  
160 prepared in accordance to the mixture of high pressure/high dose PIPAC (HP/HD-PIPAC) [10],  
161 i.e., 6 mg of doxorubicin (Accord 2 mg/ml, Accord Healthcare GmbH, Munich, Germany) was  
162 admixed with 50 ml of a 0.9 wt.-% aqueous sodium chloride solution (Ecolav<sup>®</sup> 100, B. Braun,  
163 Melsungen, Germany). Finally, the nozzles were milled open in a laminar flow workbench and  
164 macroscopic changes were documented photographically.


165 Moreover, the chemical composition of the nozzles pipes was characterised for the elements C,  
166 Si, Mn, P, S, Cr, Ni, Mo, Cu, W and N by means of spark optical emission spectral analysis  
167 (SPECTROMAXx, SPECTRO Analytical Instruments GmbH, Kleve, Germany) via an  
168 accredited laboratory (WS Material Service GmbH, Essen, Germany).

169

## 170 3 Results

### 171 3.1 Technical design and principle of operation

172 The 90° sectional views of the head regions in Figure 1 show technical details of the examined  
173 nozzles.



174

175 **Figure 1:** 90° sectional views of the head regions of the nozzles. Legend: O = outlet orifice; H = nozzle  
176 head; I = bar inlay with distal transverse borehole; M = double metal grid; N = fixed needle; S = shaft;  
177 T = twist body.

178 Externally, all nozzles consist of a stainless steel shaft (S) with a more or less pronounced nozzle  
179 head (H) on the lower part and a Luer lock thread on the upper part (not shown in Figure 1).  
180 The Luer lock threads serve for the connection of the nozzles with high-pressure injectors via  
181 high-pressure hose lines. Internally, the nozzles show partly considerable differences.




182 Interestingly, nozzle A and B are quasi identical in construction and their principle of operation,  
183 while the nozzles C and D differ significantly from them and from each other.

184 In the case of the nozzles A, B and D, the liquid drug is supplied internally from the Luer lock  
185 connector to the nozzle head via an annular gap between the outer shaft (S) and a bar inlay with  
186 distal transverse borehole (I). In contrast, the internal liquid drug supply of nozzle C occurs  
187 directly via the hollow cavity of the shaft (S). Moreover, nozzle C is equipped with a double  
188 metal grid (M) with two different mesh sizes that serve as particle filter.

189 While the nozzles A and B contain one twist body (T), nozzle D is equipped with four twist  
190 bodies (i.e., with one axial and three lateral twist bodies in 120° arrangement) to improve the  
191 spatial drug distribution within the abdominal cavity. The twist bodies (T) of the nozzles A, B  
192 and D contain longitudinally superfcially milled grooves at 180° intervals. As the liquid drug  
193 flow rate passes along the twist bodies (T) they were set into rotation that improves the  
194 aerosolisation prior leaving the nozzle via the outlet orifice (O). In the case of nozzle C, the  
195 twist body is replaced by an fixed metal needle (N). This needle contains also laterally located,  
196 spirally milled axial grooves that induce a whirlwind effect for aerosolisation when passed by  
197 the liquid flow before leaving the nozzle via the outlet orifice (O).

198 Light microscopic images of the outlet orifices (O) with determined orifice diameters of the  
199 examined nozzles are shown in Figure 2.



201 **Figure 2:** Light microscopic images of the outlet orifices with determined orifice diameters of the  
202 examined nozzles; scaling in mm.

### 203 3.2 Operational parameters based on barometric and granulometric analyses


204 Figure 3 a depicts at first the determined operational pressure over the liquid flow rate of the  
205 examined nozzles, while in Figure 3 b the mass median diameter of the of the droplet size  
206 distribution over the operational pressure is given. To avoid artefacts due clouding of the optics



207 of the laser diffraction spectrometer, the lateral nozzles of nozzle D (QuattroJet) were taped off  
208 for the granulometric analyses and a flow rate of 0.5 ml/s was chosen (manufacturer-  
209 recommended flow rate of 1.5 ml/s) Note that the shown data are determined at steady state  
210 conditions of the aerosolization process analogous to [8].

211 It can be observed in Figure 3 a that the determined operational pressure data for all examined  
212 nozzles fit well with the fluid dynamic theory, i.e., the dynamic pressure (or the dynamic  
213 pressure drop) of an incompressible fluid increases with the fluid velocity by the power of two.  
214 According to the equation of continuity, the fluid velocity of an incompressible fluid is in turn  
215 directly proportional to the volumetric liquid flow rate. The nozzles A, B and D show a similar  
216 performance regarding operational pressure and liquid flow rate, while nozzle C (MCR-4  
217 TOPOL<sup>®</sup>) has a significantly lower pressure drop and thus a considerable higher volumetric  
218 liquid flow rate at a specific operational pressure.

219 Beside the whole operational spectrum, also the manufacturer-recommended operational  
220 conditions were separately examined, i.e., at a volumetric liquid flow rate of 0.5 ml/s for nozzle  
221 A (Nebulizer), nozzle B (HurriChem<sup>TM</sup>), (1.3 - 2.0) ml/s for nozzle C (MCR-4 TOPOL<sup>®</sup>) and  
222 1.5 ml/s for nozzle D (QuattroJet). Under these preconditions nozzle C showed with (18 - 26) s  
223 the shortest initiation time to reach the corresponding steady state pressure of (7.4 – 18.1) bar,  
224 followed by nozzle A with 52 s (15.7 bar) and nozzle D with 94 s (16.0 bar). Note that with  
225 taped-off lateral nozzles, nozzle D shows a higher operational pressure of 19.3 bar (as shown  
226 in Figure 3).



227

228 **Figure 3:** Operational pressure as function of the liquid flow rate from barometric analyses (a), mass  
 229 median diameter as function of the operational pressure from granulometric analyses (b) and volume-  
 230 weighted distributions density (c) and cumulative distribution (d) of droplets at certain manufacturer-  
 231 recommended operational condition; black cycles/ellipses indicate manufacturer-recommended  
 232 operation condition.


233 Figure 3 b shows that the mass median diameter of the generated droplet aerosols depends for  
 234 each nozzle significantly on the operational pressure. With increasing operational pressure, the  
 235 mass median diameter decreases. For operational pressures of  $\leq 4$  bar, quasi no significant  
 236 difference between the different nozzles can be observed. This is attributed to a non-fully  
 237 developed aerosolization of the supplied liquid. For operation pressures of  $\geq 5$  bar stable aerosol

238 generation is reached and differences between the nozzles can be observed. For operational  
239 pressures  $\geq 5$  bar, nozzle C (MCR-4 TOPOL<sup>®</sup>) shows the coarsest mass median diameters,  
240 followed by nozzle A (Nebulizer). The finest mass median diameters were determined for  
241 nozzle B (HurriChem<sup>TM</sup>) and D (QuattroJet).

242 This ranking can also be deduced by the volume-weighted droplet size distributions of the  
243 aerosols as generated by the nozzles at the manufacturer-recommended operation conditions  
244 (Figure 3 c, Figure 3 d). Moreover, it can be observed in Figure 3 c and Figure 3 d, that each  
245 aerosol has a polydisperse and bimodal droplet size distribution.

### 246 3.3 Operational parameters based on image-metric analyses

247 Figure 4 shows photographic images for the spray cone angle (upper panel), the spray cone  
248 form (mid panel) and the horizontal drug deposition area (lower panel) of each examined nozzle  
249 as determined at manufacturer-recommended operational conditions.



250

251 **Figure 4:** Photographic images of spray cone angle (upper panel), of spray cone form (middle panel)  
252 and horizontal drug deposition area (lower panel, scale in cm).

253 According to the upper panel of Figure 4, the widest single spray cone angle was determined  
254 with  $79^\circ$  for nozzle C (MCR-4 TOPOL<sup>®</sup>), followed with  $72^\circ$  for nozzle A (Nebulizer) and with  
255  $71^\circ$  for nozzle B (HurriChem<sup>TM</sup>). Nozzle D (QuattroJet) shows with  $67^\circ$  the smallest single  
256 spray cone angel, but it has to keep in mind that nozzle D contains in contrast to the other  
257 nozzles of four spray cones. Moreover, it can be observed from the middle panel of Figure 4  
258 that nozzle A (Nebulizer), nozzle B (HurriChem<sup>TM</sup>) and nozzle D (QuattroJet) generate a full  
259 spray cone, whereas nozzle C (MCR-4 TOPOL<sup>®</sup>) produces a hollow spray cone. The full spray  
260 cones of the nozzles A, B and C lead also to complete filled circular areas of horizontal drug  
261 deposition beneath the nozzles as shown in the lower panel of Figure 4. In the case of the nozzles  
262 A and B, a circular deposition area of approx.  $38.5 \text{ cm}^2$  (outer diameter of approx. 7 cm) was  
263 determined. The lateral outlets of nozzle D showed beside the axial circle (outer diameter of  
264 approx. 7 cm) also 3 additional deposition areas of  $(13 \times 20) \text{ cm}$  that cumulates to an overall  
265 horizontal deposition area of approx.  $679 \text{ cm}^2$ .

### 266 3.5 *Chemical resistance and chemical composition*

267 Photographic images of the nozzle parts after the exposure to the cytostatic solution are shown  
268 in Figure 5.



269 **Figure 5:** Photographic images of the nozzle parts after exposure to the cytostatic solution.

271 Figure 5 shows that in the case of nozzle C (MCR-4 TOPOL<sup>®</sup>) the exposure to the cytostatic  
272 solution led to the formation of iron oxide. These are particularly pronounced on the fine-mesh  
273 particle filter, the nozzle needle and the nozzle head housing. No changes were observed for  
274 the nozzles A, B and D either visually or by light microscopic analyses.

275 The nozzles A, B and D fulfil all requirements according to EN 10088-3:2014 [11] on the  
276 chemical composition of stainless steel 1.4301 that is typically used for surgical instruments.



277 Beside a twelve times higher quantity of sulphur (0.012 wt.-% vs. 0.001wt.-%), also quantities  
278 of molybdenum (0.183 wt.-%), copper (0.220 wt.-%) and tungsten (0.134wt.-%) were  
279 identified by spark optical emission spectrometry for nozzle C (MCR-4 TOPOL®).

280

## 281 4 Discussion

282 Due to the current lack of knowledge, four clinically-operated nebulising nozzles for PIPAC  
283 were comparatively tested regarding their performance. The most important determined  
284 technical characteristics of these nozzles are summarised in Table 1.

285 **Table 1:** Overview on technical and functional characteristics of the examined nozzles; \* =  
286 manufacturer-recommended operational conditions.

parameter	unit	A (Nebulizer)	B (HurriChem™)	C (MCR-4 TOPOL®)	D (QuattroJet)
*liquid flow rate (*Q <sub>L</sub> )	ml/s	0.5	0.5	1.3 - 2.0	1.5
operational pressure for *Q <sub>L</sub>	bar	15.7	14.9	7.4 – 18.1	16.0
pressure initiation time for *Q <sub>L</sub>	s	52	100	18 - 26	94
nozzle orifice diameter	µm	200	190	370	170
mass median diameter for 15 bar	µm	28.95	20.99	52.17	24.18
max. spray angle for *Q <sub>L</sub>	°	≈ 72	≈ 71	≈ 79	≈ 67
number of nozzles	-	1 × axial	1 × axial	1 × axial	1 × axial, 3 × lateral
kind of spray cone	-	full cone	full cone	hollow cone	full cone
drug deposition area for *Q <sub>L</sub>	cm <sup>2</sup>	≈ 38.5	≈ 38.5	≈ 66	≈ 679

287

288 Nozzle A (Nebulizer) shows after an initiation time of 52 s an operational pressure of 15.7 bar  
289 at the manufacturer-recommended operational liquid flow rate of 0.5 ml/s. Thereby, a full spray  
290 jet cone (71°) composed of droplets with a mass median diameter of 29 µm is formed. The  
291 determined data of this study reveal that nozzle A is identical in design and performance to the  
292 primary for PIPAC developed predecessor, i.e., the microinjection pump MIP [8], which was  
293 also distributed under the tradename CapnoPen.

294 Nozzle B (HurriChem™) is another launched nebulizer for PIPAC. Examinations on design  
295 and principle of operation show a high similarity with nozzle A (Nebulizer) and thus also with  
296 the initial PIPAC nozzle technology. At the manufacturer-recommended operational liquid flow  
297 rate of 0.5 ml/s, nozzle B shows after an initiation time of 100 s an operational pressure of

298 14.9 bar. The mass median diameter of the droplets in the formed full spray jet cone (73°) was  
299 determined to be 21 µm.

300 Nozzle C (MCR-4 TOPOL®) differs in technical design, principle of operation, operational  
301 parameter and aerosol characteristics significantly from all other investigated nozzles. The  
302 operation of nozzle C is accompanied by the formation of a hollow spray cone jet (79°). At the  
303 manufacturer-recommended operational liquid flow rate range of (1.3 – 2.0) ml/s, operational  
304 pressures of (7.4 – 18.1) bar were reached within short initiation times of (18 – 26) s. The mass  
305 median droplet size decreases with increasing liquid flow rate, but was found to be in each case  
306 larger than 50 µm.

307 Nozzle D (QuattroJet) is a further PIPAC nebulizing nozzle that was introduced by the  
308 manufacturer of nozzle A. To optimize the spatial drug distribution pattern and higher  
309 intraabdominal aerosol particle concentration, the conventional axial nozzle is supplemented in  
310 nozzle D by three further nozzles, which are arranged lateral at the nozzle head with an angular  
311 distance of 120°. Nozzle D is based on the same technology as nozzle A. At the manufacturer-  
312 recommended flow rate of 1.5 ml/s, nozzle D shows an operational pressure of 16.0 bar after  
313 an initiation time of 92 s and provides four full spray cone jets (67°) composed of droplets with  
314 a mass median diameter of 21 µm.

315 Recently, a first attempt regarding recommendations on the minimum technical requirements  
316 on nozzles suitable for PIPAC treatment was published. A minimum requirement for the spray  
317 angle of at least 70° was defined [12] by implying that the spray cone angle corresponds to the  
318 achievable drug deposition area. But there are two limitations found in this study that contradict  
319 this requirement. The present study shows that the requirement is matched directly by nozzle  
320 A, B and C. But despite of a slightly lower spray cone angle of 67° than required, nozzle D  
321 consists of four spatially-displaced spray jets cumulating in a total spray angle of 268°. On the  
322 other hand, Nozzle C, unlike all other nozzles examined, had a hollow spray cone, resulting in  
323 a ring-shaped drug deposition area that was smaller than that of a full spray cone jet at the same  
324 spray cone angle. With regard on the nozzle performance, the drug deposition area seems to be  
325 an even better technical parameter than the spray cone angle.

326 The examined nozzles C (MCR-4 TOPOL®) and D (QuattroJet) of this study show in contrast  
327 to A (Nebulizer) and B (HurriChem™) and thus in contrast to the primary PIPAC nozzle  
328 technology significant differences in their principle of operation and performance. Nozzle C

329 offers the largest spray cone angle of all examined nozzles, but also a hollow spray cone. It is  
330 not evident if such a spray jet improves drug distribution and drug penetration, since so far as  
331 known there are no preclinical studies comparing a hollow with a full spray cone. Nozzle D  
332 provides multiple spray cones that can significantly improve the spatial drug distribution by  
333 reduction of high local deposition and thus high local tissue toxicity. Nonetheless, these  
334 potential benefits of multi-nozzle systems need to be confirmed by further research.

335 A worrying result of this study was, that nozzle C (MCR-4 TOPOL<sup>®</sup>) shows in contrast to the  
336 other nozzles a macroscopically visible formation of iron oxide after long-term exposure in a  
337 sodium chloride containing cytostatic solution. Based on spark optical emission spectrometry,  
338 it was found that this nozzle was made from a steel that, in addition to a 12-fold higher sulphur  
339 content (0.012 wt.-% vs. 0.001 wt.-%), also contained amounts of molybdenum (0.183 wt.-%),  
340 copper (0.220 wt.-%) and tungsten (0.134 wt.-%). Short-term exposure of the nebulizers to  
341 cytostatic solution shows no immediate corrosion, but a possible risk for the patient cannot be  
342 completely ruled out. This leads to the conclusion that manufacturer and regulatory authorities  
343 for medical devices accreditation must also critically assess the suitability of specific steel  
344 alloys for the administration of cytostatic drugs in their risk assessment.

345 Currently, there are only limited preclinical data to suggest that there is an optimal technique  
346 for the generation and delivery of PIPAC aerosols that could improve clinical outcome.  
347 However, it is clear that, contrary to claims made by one manufacturer [13], larger aerosol  
348 droplets injected into the peritoneal cavity at higher velocities with a hollow spray cone do not  
349 improve either the spatial distribution pattern [8, 14] or tissue penetration depth per se.  
350 Nebulizers differing from the present standard technology in its design, especially in its  
351 spraying characteristics, cannot automatically be considered equivalent by the clinical user.  
352 Therefore, before their broad clinical use, the individual innovation phases should be  
353 systematically tested, ideally following the recommendation of the IDEAL-D framework for  
354 the introduction of medical devices [15, 16]. While the original nozzle technology has  
355 completed phase I - IIb [17] and phase III trials are ongoing [4, 5], only limited phase I clinical  
356 user data has been published for nozzle C (MCR-4 Topol<sup>®</sup>) [18]. Such data are lacking for  
357 nozzle B and D.

358 In the near future, clinical users should be able to rely on technical testing and reporting being  
359 based on scientific standards and generally applicable global standards, such as ISO standards.  
360 For PIPAC nebulizers, such standards should ideally be set by a panel of experts through



361 consensus conferences. Moreover, nebulizers with significant technical and granulometric  
362 differences from the standard technology should undergo first ex- and in-vivo animal testing  
363 before their first clinical use. Manufacturers should be obliged to have the bioequivalence of  
364 the cytostatic drugs administered independently certified in comparison to standard nebulizer  
365 systems, analogous to drugs and their generics. Relevant outcome measures are aerosol  
366 characteristics, spatial drug distribution, depth of penetration, tissue concentration and the peak  
367 concentration and the area under the curve describing the extent of peritoneal passage [8, 19 -  
368 28]. The ratio between the individual properties of the generic nebulizer and the reference  
369 product would ideally be 1:1 in case of bioequivalence. Since this is unlikely to be achieved,  
370 the US Food and Drug Administration (FDA), for example, requires that the 90% confidence  
371 interval should be between 0.80 and 1.25 [29]. Similar to the FDA specifications, new PIPAC  
372 nozzle technologies could be tested comparatively in the future. Such preclinical testing, ideally  
373 using standardized models, could prevent the use of such devices from compromising clinical  
374 outcomes and/or harming healthcare professionals/patients. Finally, it would be helpful for the  
375 comparability of clinical results if the nebulizer type used in each case will be also recorded in  
376 the PIPAC database (<https://isspp.org/professionals/pipac-database/>).

377

## 378 **5 Conclusion**

379 Four clinically-used nozzles to aerosolise chemotherapeutic drugs in the context of Pressurized  
380 Intraperitoneal Aerosol Chemotherapy (PIPAC), i.e., the Nebulizer, the HurriChem<sup>TM</sup>, the  
381 MCR-4 TOPOL<sup>®</sup> and the QuattroJet were examined comparative to determine their  
382 performance.

383 It could be confirmed that the Nebulizer shows quasi an identical technical design and thus also  
384 a similar performance as the original PIPAC nozzles MIP/CapnoPen. The PIPAC nozzle  
385 HurriChem<sup>TM</sup> is based on a similar technical design as the Nebulizer nozzle, but provides a  
386 finer aerosol due to a smaller nozzle orifice opening. Both, the MCR-4 TOPOL<sup>®</sup> and the  
387 QuattroJet deviate in the principles of operations to that of the Nebulizer and thus to the original  
388 PIPAC technology. While the MCR-4 TOPOL<sup>®</sup> provides the coarsest aerosol of all examined  
389 nozzles, the QuattroJet delivers an aerosol similar to that of the HurriChem<sup>TM</sup>. In contrast to the  
390 HurriChem<sup>TM</sup>, the QuattroJet<sup>®</sup> comes with the feature of four spray cones (one axial, three  
391 lateral) to improve the spatial drug distribution and a higher aerosol particle number  
392 concentration.

393 The availability of new PIPAC nozzles with special features is encouraging, but can also have  
394 a negative impact for establishment of the promising PIPAC approach for the treatment of  
395 peritoneal carcinomatosis, if their performance and efficacy is unknown. It is therefore  
396 recommended that nozzles for which the technical/granulometric characteristics differ from the  
397 current standard technology must be subjected to preclinical proof of equivalence in terms of  
398 spatial drug distribution, tissue penetration and concentration before routine clinical use. It is  
399 expected that representative in-silico models like the ones used in [23, 24] will be available in  
400 the near future. New nebulizers should be investigated and introduced for clinical use in  
401 accordance with the IDEAL-D framework.

402

## 403 **References**

- 404 1. Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA Description of a novel  
405 approach for intraperitoneal drug delivery and the related device. *Surg. Endosc.*  
406 2012;26(7):1849–1855. Doi: 10.1007/s00464-012-2148-0.
- 407 2. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal  
408 carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence  
409 for efficacy. *Ann. Surg. Oncol.* 2014;21(2):553–559. Doi: 10.1245/s10434-013-3213-1.
- 410 3. Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy:  
411 rationale, evidence, and potential indications. *Lancet Oncol.* 2019;20(7):e368–e377. Doi:  
412 10.1016/S1470-2045(19)30318-3
- 413 4. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC Pressurized IntraPeritoneal Aerosol  
414 Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases  
415 secondary to platinum resistant ovarian cancer – study protocol for a randomized control  
416 trial. *Pleura and Peritoneum* 2019;4(1). Doi: 10.1515/pp-2018-0111
- 417 5. Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy  
418 (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer:  
419 a randomized multicenter phase III trial PIPAC VEROne. *Pleura and Peritoneum*  
420 2022;7(3):135–141. Doi: 10.1515/pp-2022-0111
- 421 6. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal  
422 aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?  
423 *European Journal of Surgical Oncology* 2021;47(1):149–156. Doi:  
424 10.1016/j.ejso.2020.08.020
- 425 7. Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in  
426 pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura and Peritoneum*  
427 2022;7(1):1–7. Doi: 10.1515/pp-2022-0102
- 428 8. Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the micro  
429 injection pump (MIP®) and granulometric characterization of the aerosol applied for  
430 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). *Surg. Endosc.*  
431 2017;31(4):1778–1784. Doi: 10.1007/s00464-016-5174-5
- 432 9. Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming Drug Resistance by Taking  
433 Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy  
434 (PIPAC). *Cancers* 2020;12(1):34. Doi: 10.3390/cancers12010034.

- 435 10. Arias GR, Sindayigaya R, Ouaiissi M, et al. Safety and Feasibility of High-Pressure/High-  
436 Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and  
437 Metastatic Peritoneal Surface Malignancies. *Ann. Surg. Oncol.* 2022. Doi: 10.1245/s10434-  
438 022-12698-4.
- 439 11. EN 10088-3:2014. Stainless steels - Part 3: Technical delivery conditions for semi-finished  
440 products, bars, rods, wire, sections and bright products of corrosion resisting steels for  
441 general purpose.
- 442 12. Pocard M, So JBY, Huchon C, et al. PIPAC nebulizer: How to test the new devices in the  
443 market, expert recommendations. *Journal of Visceral Surgery* 2022. Doi:  
444 10.1016/j.jviscsurg.2022.10.001.
- 445 13. PIPAC – Pressurized Intraperitoneal Aerosol Chemotherapy; [https://www.skala.cz/en/mcr-  
446 4-topol-en/](https://www.skala.cz/en/mcr-4-topol-en/) (access: 5<sup>th</sup> March 2023 at 11:02 CET)
- 447 14. Hinds, William C. (1999). *Aerosol technology: properties, behaviour, and measurement of*  
448 *airborne particles*. New York: Wiley. ISBN 978-0-471-19410-1.
- 449 15. Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P IDEAL-D: a rational  
450 framework for evaluating and regulating the use of medical devices. *Br. Med. J.* 2016;i2372.  
451 Doi: 10.1136/bmj.i2372.
- 452 16. Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P Beyond the RCT: When  
453 are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We  
454 Do Instead? *Ann. Surg.* 2021;275(2):324–331. Doi: 10.1097/SLA.0000000000005053.
- 455 17. Baggaley AE, Lafaurie GBRC, Tate SJ, et al. Pressurized intraperitoneal aerosol  
456 chemotherapy (PIPAC): updated systematic review using the IDEAL framework. *Br. J.*  
457 *Surg.* 2022;110(1):10–18. Doi: 10.1093/bjs/znac284.
- 458 18. Hoskovec D, Dytrych P, Vocka M, Krska Z, Skala R MCR-4 TOPOL® new device for  
459 PIPAC – first clinical use. *Eur. J. Surg. Oncol.* 2022;48(2):e155. Doi:  
460 10.1016/j.ejso.2021.12.308.
- 461 19. Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W Optimization  
462 of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and  
463 Experimental Study. *Scientific Reports* 2021;12(1). Doi: 10.1038/s41598-022-10369-8.
- 464 20. Göhler D, Geldner A, Gritzki R, et al. Development of a rat capnoperitoneum phantom  
465 (RCP) to study drug aerosol deposition in the context of anticancer research on peritoneal  
466 carcinomatosis. *Sci. Rep.* 2021;11:21843. Doi: 10.1038/s41598-021-01332-0.

- 467 21. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nano-aerosol therapy  
468 (HINAT) as improved approach for pressurised intraperitoneal aerosol chemotherapy  
469 (PIPAC): Technical description, experimental validation and first proof of concept.  
470 Beilstein J. Nanotechnol. 2017;8:2729–2740. Doi: 10.3762/bjnano.8.272.
- 471 22. Buggisch JR, Göhler D, Sobilo J, et al. Development and technical validation of an  
472 ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer  
473 peritoneal metastases model. BMC Cancer 2022;22(570). Doi: 10.1186/s12885-022-09668-  
474 0.
- 475 23. Rezniczek GA, Buggisch J, Sobilo J, et al. Establishment of a mouse ovarian cancer and  
476 peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers 2020;12(12).  
477 Doi: 10.3390/cancers12123818.
- 478 24. Höltzcke P, Sautkin I, Clere S, Castagna A, Königsrainer A, Pott PP, Reymond MA.  
479 Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol  
480 generator (usPIPAC). Surg Endosc. 2022 Oct;36(10):7848-7858. doi: 10.1007/s00464-022-  
481 09525-y. Epub 2022 Aug 29. PMID: 36038646; PMCID: PMC9485099.
- 482 25. Toussaint L, Sautkin Y, Illing B, Weinreich FJ, Nadiradze G, Königsrainer A, Wichmann  
483 D. Correction to: Comparison between microcatheter and nebulizer for generating  
484 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg Endosc. 2021  
485 Aug;35(8):4901. doi: 10.1007/s00464-021-08577-w. Erratum for: Surg Endosc. 2021  
486 Apr;35(4):1636-1643. PMID: 34106308; PMCID: PMC8263410.
- 487 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a  
488 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.  
489 PMID: 33842275; PMCID: PMC8033043.
- 490 27. Mimouni, M., Richard, C., Adenot, P. et al. Pressurized intra-peritoneal aerosol  
491 chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution  
492 patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer  
493 21, 461 (2021). <https://doi.org/10.1186/s12885-021-07955-w>
- 494 28. Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations  
495 of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann  
496 Surg Oncol 26, 4445–4451 (2019). <https://doi.org/10.1245/s10434-019-07695-z>  
497

- 498 29. Andrade C Bioequivalence of Generic Drugs: A Simple Explanation for a US Food and  
499 Drug Administration Requirement. *Journal of Clinical Psychiatry* 2015;76(06):e742–e744.  
500 Doi: 10.4088/JCP.15f10094.